Stay updated with breaking news from Davidj Chang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PHILADELPHIA, Feb. 01, 2024 -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with...
Throughout 2023, interest in the application of CAR-T and other cell therapies to autoimmune disease skyrocketed, with a multitude of clinical trials being initiated by various companies.
The FDA has granted Fast Track designation to CABA-201 for the treatment of systemic lupus erythematosus and lupus nephritis.
The cellular therapy depletes CD19-positive B cells with the goal of 'resetting' the immune system to achieve durable remission.
The FDA has granted fast-track designation to CABA-201, a CD19-CAR T cell investigational therapy, for the treatment of systemic lupus erythematous and lupus nephritis, according to a press release from the manufacturer.